Quarterly report · Q2
9776.TEDINET S100S73T
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥291m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥493m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥296m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥589m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥386m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥508m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥569m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥258m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥319m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥16.7bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥16.2bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥5.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.0bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥10.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.5bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥810m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥674m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥171m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥409m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥292m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥238m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥348m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥223m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥67.94 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.23 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥170.53 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥77.37 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥54.09 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 64.4% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥56m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥41m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥78m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥377m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥798m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥492m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥7m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥448m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥308m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥489m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥46m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥44m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥371m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥356m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥805m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥472m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥333m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥6m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥333m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥721m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥334m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥751m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 549
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)清明監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)加賀 聡 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)原田 一平 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 9964353000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 9862397000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 20127692000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 589456000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 296350000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 1159449000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 258282000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 226295000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 568619000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 312111000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 251769000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 649366000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 10543730000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 11024152000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 10880986000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 16234132000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 16712144000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 16521281000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 77.37 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 67.94 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 170.53 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.632 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.644 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.641 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 673789000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 809541000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 1430350000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | 292136000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -170535000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -409028000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -223483000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -237969000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -347894000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 3723063000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 4055085000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 3654048000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 54.09 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 66.23 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4216000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4216000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 4216000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 4216000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |